// App-Quantinova.ai

1465 : The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia

Researchers

Presenter

  • C. Michel Zwaan

Principal Investigators

  • Carla Exalto

  • Troels Koch

  • Huib N. Caron

  • Rob Pieters

  • Monique L. den Boer

  • Mirjam W.J. Luijendijk

  • Valerie S. Calvert

  • Emanuel F. Petricoin

  • William E. Evans

  • Dirk Reinhardt

  • Valerie de Haas

  • Maj Hedtjarn

  • Bo R. Hansen

Medical Centers

  • Dutch Childhood Oncology Group, The Hague, Netherlands.

  • Hannover Medical School, AML-BFM Study Group, Hannover, Germany

  • Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

  • Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA

  • Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA

  • Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

Locations

  • United States

  • Germany

  • Netherlands

Companies

  • Santaris Pharma A/S

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Acute Leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Nucleoside diphosphate kinase A

Drug/Treatment

  • AZD-1152-hQPA

  • barasertib

  • Danusertib

  • Alisertib

  • AZD-1152

  • Tozasertib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved